CVS Health Misses 2026 Profit Forecast, Shares Drop
CVS Health falls short of Wall Street's 2026 profit expectations despite beating Q4 estimates. Stock drops 3% as company maintains cautious outlook amid healthcare industry challenges.
/ 902 items
#Healthcare↓
FDA Rejects Regenxbio's Gene Therapy for Hunter Syndrome After Clinical Hold
FDA issues Complete Response Letter rejecting RGX-121 gene therapy for Hunter syndrome, citing trial design concerns. Regenxbio plans to resubmit with additional data.
Wedbush Starts Coverage on Zura Bio with Positive Outlook
Wedbush gives Zura Bio an Outperform rating and $15 target, highlighting upcoming clinical catalysts and potential stock growth through 2026.
Novo Nordisk Sues Hims & Hers Over Weight-Loss Drug Knockoffs
Danish pharma giant Novo Nordisk files patent lawsuit against telehealth company Hims & Hers for selling unauthorized versions of Wegovy and Ozempic weight-loss medications.
Lilly Acquires Orna Therapeutics for Up to $2.4 Billion
Eli Lilly acquires Orna Therapeutics to advance groundbreaking in vivo CAR-T therapies for autoimmune diseases using circular RNA technology.
Wells Fargo Upgrades GeneDx: Analysts See Strong Upside After Stock Drop
Wells Fargo upgrades GeneDx to Overweight, saying the recent stock decline looks excessive and growth opportunities could drive momentum into 2026.